spartalizumab   Click here for help

GtoPdb Ligand ID: 10140

Synonyms: NPV-PDR001 | NPVPDR001 | PDR-001 | PDR001
Immunopharmacology Ligand
Compound class: Antibody
Comment: Spartalizumab (PDR001) is a humanized, IgG4κ anti-PD-1 monoclonal antibody immuno-oncology lead that is being developed by Novartis.
Sequence and structural information about this antibody are available from its IMGT/mAb-DB entry. BLAST analysis of the peptide sequences submitted to the WHO for the INN spartalizumab reveal exact matches with peptide sequences claimed in patent US9683048B2 [1], specifically SEQ ID NO: 91 for the entire heavy chain and SEQ ID NO: 72 for the entire light chain. Sequence IDs 91 and 72 are components of the antibody designated as BAP049-Clone-E which is one of the humanized clones generated in the discovery campaign described in US9683048B2.
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
10624 spartalizumab
Synonyms Click here for help
NPV-PDR001 | NPVPDR001 | PDR-001 | PDR001
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 761
Other databases
GtoPdb PubChem SID 381118850
Search PubMed clinical trials spartalizumab
Search PubMed titles spartalizumab
Search PubMed titles/abstracts spartalizumab